Ark Diagnostics specializes in the development and manufacturing of in vitro diagnostic immunoassays aimed at therapeutic drug monitoring and urine drug testing. Their product line includes a variety of assays for the quantitative and qualitative detection of drugs such as methotrexate, hydrocodone, and levetiracetam, among others. The company emphasizes the use of homogeneous enzyme immunoassay technology, which enhances the sensitivity and efficiency of clinical laboratory testing. Their assays are designed to be liquid, stable, and ready-to-use, facilitating convenience in clinical settings.

In addition to their established products, Ark Diagnostics is actively developing new assays for various applications, including epilepsy, cancer, antibiotics, and antiretroviral drugs. Their offerings are CE marked and FDA cleared, ensuring compliance with regulatory standards for safety and efficacy. The company also provides specialized assays for forensic use, such as the detection of ethyl glucuronide in urine, which is particularly relevant in criminal justice contexts. Overall, Ark Diagnostics is committed to advancing healthcare through innovative diagnostic solutions that support accurate drug monitoring and testing.

United States

ARK Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK's proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. ARK is dedicated to improving the quality of patient health through better therapeutic drug management. (ARK Diagnostics, Inc. seeks regulatory clearance in the United States and Internationally.)

Ark Diagnostics

Company Details